Fig. 3From: Dendritic cell-mediated chronic low-grade inflammation is regulated by the RAGE-TLR4-PKCβ1 signaling pathway in diabetic atherosclerosisRAGE antibodies and TLR4 inhibitors inhibit the immune maturation of DCs. After pretreatment with RAGE neutralizing antibody, the expression of CD83 and CD86 were decreased, and accompanied by a significant down-regulation of secretion of the inflammatory cytokines and IκB/NF-κB phosphorylation (a–c). In the TLR4 inhibitor group, CD83 and CD86 were down-regulated, and the ability of BMDCs to release inflammatory cytokines also was decreased (d, e). Combined with the decreased expression of p-NF-κB and p-IκB (f). Values, mean ± SED; n = 3, *p < 0.05 vs. oxLDL + AGEs group; oxLDL oxidized low density lipoprotein, AGEs advanced glycation end-products; RAGE Receptor for advanced glycation end products, NF-κB nuclear factor-κB, IFNγ IFN gamma; TLR4 Toll-like receptor 4, TNFα Tumor necrosis factor alphaBack to article page